Kevin Church, Chief Science Officer of Athira Pharma, joins Suzanne to talk about what happens to the brain when someone has Alzheimer's. It's a very complex disease. Most people know about the amyloid plaques that causes neuro-degeneration. Other proteins also build up. These clumps interrupt memory formation, communication between nerve cells, and regardless of the clumps, the ultimate problem is that the nerves aren't working properly and are dying. Right now there are limited treatments for those diagnosed with Alzheimers. Athira's clinical trials with fosgonimeton aim to keep nerve cells alive in the face of these clumps. It helps reduce inflammation, and it's shown promise in their trials.

If you're a caregiver or an adult child, if you're interested in participating in a clinical trial, talk to a specialist to see if it's appropriate. Talk to your doctor or neurologist, or a specialist at a clinic — visit clinicaltrials.gov for trials in your area, and the LIFT-AD Clinical Trial website for Athira Pharma's trials. See AFE's Alzheimer's and Dementia page and AFE's Athira Pharma podcasts page for more shows about these topics. Courtesy of Athira Pharma.

See omnystudio.com/listener for privacy information.